Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 30 (BNIP3P30) is classified as a noncoding pseudogene, meaning it is a DNA sequence similar to the protein-coding gene BNIP3 but does not encode a functional protein[1][5]. Pseudogenes may, in some cases, have regulatory functions at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or regulating their parent gene's expression. However, there is no evidence that BNIP3P30 has a validated role in any molecular pathway, disease process, or as a drug target. Any functional roles described in the literature relate to other BNIP3 pseudogenes or the functional BNIP3 gene, not BNIP3P30 specifically[1][2][5]. Therefore, BNIP3P30 is not considered a therapeutic target and its mention as a receptor or enzyme is incorrect.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 30 (BNIP3P30).